AI Article Synopsis
- The study investigates the pregnancy outcomes of women with antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPL) who have had five or more pregnancies (grand multiparity) and compares them to two control groups: those with fewer pregnancies and those without aPL/APS.
- Results showed that while most pregnancy-related parameters were similar across the groups, grand multiparity women with aPL/APS had higher rates of obstetric APS diagnosis, older maternal age, higher body mass index (BMI), more cases of polyhydramnios, and delivered larger babies.
- The conclusions suggest that the perinatal outcomes for grand multiparity women with aPL/APS are not worse than those of their counterparts
Article Abstract
Objective: In recent years antiphospholipid syndrome (APS) as well as antiphospholipid antibodies (aPL) prevalence has demonstrated an upward trend in women during reproductive age. There is a lack of data concerning its effects on women with grand multiparity (GMP) (parity ≥5). Hence, this study aimed to assess pregnancy outcomes among GMP aPL/APS patients.
Study Design: We retrospectively assembled the births of GMP women with aPL/APS, between 2017 and 2022 in the Sheba Medical Center. We compared their deliveries with those of two control groups: (1) the "aPL/APS-controls"-of pregnant women with aPL/APS and parity <5. (2) The "GMP-controls"- parity ≥5 without aPL/APS. We examined demographics, aPL characteristics, pregnancy, and neonatal outcomes between the groups.
Results: In total, 42 deliveries in the study group were compared to 461 deliveries in the "aPL/APS-controls" group and 84 deliveries of the "GMP-controls." Most parameters were similar across groups. However, the study group had a higher rate of obstetric APS diagnosis (64.64% vs. 83.33%, p < 0.01) and showed significant differences such as older maternal age, higher BMI, more polyhydramnios cases, and larger babies compared to controls (33.91 vs. 36.19, p = 0.05; 23.2 vs. 28.89, p = 0.02; 3.68 vs. 11.9, p = 0.01; and 2.17 vs. 14.28, p < 0.01, respectively).
Conclusions: Our findings reveal that perinatal outcomes in aPL/APS GMP women are comparable and not inferior to those in aPL/APS women with <5 pregnancies or in comparison to the general GMP population. The minor differences observed may all be related to GMP women's older age and higher BMI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/aji.70013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tranexamic Acid in Pregnant Women With Placenta Previa: A Double-Blind, Multicenter Randomized Clinical Trial.
Cureus
December 2024
Obstetrics and Gynecology, Duhok Obstetrics and Gynecology Teaching Hospital, Duhok, IRQ.
Aims: To determine the effectiveness of tranexamic acid (TXA) in reducing vaginal bleeding, extending pregnancy duration, and enhancing perinatal outcomes in pregnant women with placenta previa.
Methods: A multicenter, randomized, double-blind clinical trial was conducted at three maternity teaching hospitals in Iraq's Kurdistan region, Azadi Hospital in the north of Iraq, and Al-Azhar University Hospital in Egypt on 146 women with placenta previa. Participants were randomly assigned to two interventional groups in a 1:1 ratio to receive either TXA or Dextrose 5% water (D5W).
Magnitude and factors associated with low birth weight among newborns in public health facilities of Mekelle City, northern Ethiopia: a multi-center study.
Front Pediatr
December 2024
Department of Midwifery, College of Medicine and Health Sciences, Adigrat University, Adigrat, Ethiopia.
Background: Low birth weight is a key determinant of child survival, significantly influencing rates of infant and childhood mortality, morbidity, and disability. While some studies have been conducted in our region, there is still a gap in evidence regarding the maternal characteristics associated with low birth weight. Hence, this study aimed to determine the proportion of newborns with low birth weight and determinant factors, particularly focusing on maternal characteristics.
View Article and Find Full Text PDFAcute severe ulcerative colitis (ASUC) in pregnancy poses a clinical challenge with significant risk to both mother and fetus. Anti-TNF alpha therapy is known to be safe in pregnancy, however, data surrounding outcomes in ASUC is limited. In this report, we present the case of a pregnant patient of 10 weeks' gestation with ASUC successfully managed with intensified and accelerated infliximab therapy for a total dose of 35 mg/kg during a single admission.
View Article and Find Full Text PDFVaricocele repair for severe oligoasthenoteratozoospermia: Scoping review of published guidelines, and systematic review of the literature.
Arab J Urol
September 2024
Department of Surgery, Hamad Medical Corporation, Doha, Qatar.
Background: The outcomes of varicocele repair (VR) for severe oligozooasthenoteratozoospermia (OAT) have not been widely examined.
Methods: Assessment of outcomes of VR after severe OAT, employing scoping review of published guidelines, and systematic review of literature. The Newcastle-Ottawa scale appraised the quality of included studies.
Does age matter? Impact of age on testicular function and pregnancy outcomes following microsurgical varicocelectomy in patients with grade 3 varicocele.
Arab J Urol
September 2024
Department of Urology, Hamad Medical Corporation, Doha, Qatar.
Objective: To evaluate the effects of age on semen and hormonal parameters following microsurgical varicocelectomy among patients with grade 3 varicocele, and to compare fertility outcomes between younger (<40 years) and older (≥40 years) men.
Methods: Retrospective cohort study of infertile patients with clinical left grade 3 varicocele who underwent microsurgical subinguinal varicocelectomy (MV). Patients meeting the inclusion criteria ( = 550) were divided into two groups based on their age at the time of MV: <40 ( = 441) and ≥40 years ( = 109).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!